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Summary. 
This study examined the effect of various doses of mag-
nesium sulphate on the reperfusion injury in patients 
subjected to coronary artery bypass surgery. 
Intravenous magnesium sulphate (0, 2, 4 and 6 g) was 
administered from the onset of surgery up to the release 
of the aortic cross-clamp. General haemodynamics, 
pharmacological support of the circulation, CK-MB 
fraction and Q-wave changes were monitored. In addi-
tion, the incidence and severity of reperfusion ventricu-
lar tachycardia or fibrillation were recorded. 
A total of 138 patients were successfully randomised 
into one of the groups. There was no difference in the 
demographics, general haemodynamics or arrhythmias 
between groups either before or after surgery. 
Results of this study do not support the use of magne-
sium (as per our protocol) as an effective method of lim-
iting the reperfusion injury after cardiac surgery. 
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Cross-clamping the aorta during cardiac surgery results in 
varying degrees of myocardial ischaemia. Once the cross-
clamp is removed, reperfusion of the myocardium intro-
duces the risk of reperfusion injury, which consists of 
arrhythmias, prolonged reversible myocardial dysfunction 
(stunning) and accelerated cell death.] A current and popular 
view of the pathophysiology of the reperfusion injury is that 
free oxygen radicals are initially formed, with subsequent 
intracellular ·calcium overload .2.4 Whether this is the only 
explanation for the reperfusion injury and whether this 
sequence is necessarily the final and correct one, is still 
uncertain. However, drugs which antagonise the free oxy-
gen radicals or limit intracellular calcium overload, attenu-
ate the reperfusion injury.'·7 
Magnesium has been termed 'nature's calcium antago-
nist',8 and experimental studies have shown that increasing 
the magnesium concentration before initiation of reperfu-
sion decreases myocardial stunning,9 while animals fed a 
magnesium-poor diet demonstrated increased myocardial 
stunning once reperfusion occurred.1O Our own study on the 
effect of magnesium on the reperfusion injury in an open-
chest porcine model also demonstrated beneficial effects if 
inagnesium was administered before reperfusion." When 
magnesium was administered after myocardial infarction in 
humans, a large clinical study demonstrated beneficial 
effects.I2 However, a subsequent study failed to confirm the 
initial results.13 
The aim of this study was to evaluate the effect of mag-
nesium on the reperfusion injury when administered before 
initiation ofreperfusion. For this we chose the human model 
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the known pathophysiology and animal experiments, our 
hypothesis was that magnesium should have beneficial 
effects on the reperfusion injury. 
Methods 
Permission for the study was obtained from the Ethics 
Committee of the Faculty of Medicine at the University of 
Stellenbosch and informed consent was obtained from the 
patients before surgery. 
One hundred and forty-two consecutive patients sched-
uled to undergo artery bypass surgery (CABG) were 
enrolled in the study. Only patients with New York Heart 
Association (NYHA) grade IV for dyspnoea were excluded. 
Patients were seen the day before surgery and premedica-
tion consisted of morphine 0.1 mg/kg and promethazine 
(Phenergan) 0.4 mg/kg. They continued with their chronic 
treatment until the morning of surgery. 
In the anaesthetic suite an ECG was attached and intra-
venous and intra-arterial lines were inserted under local anaes-
thesia. A central venous pressure (CVP) line or pulmonary 
artery catheter was inserted via the internal jugular vein. 
Beta-adrenergic blockade was instituted with either ace-
butolol 0.2 mg/kg - 0.5 mg/kg, or esmolol 100 - 500 
pg/kg/min unless contraindicated. Glycopyrrolate was given 
(0.01 mg/kg) intravenously thereafter. 
While breathing oxygen, a fentanyl or sufentanil infusion 
was started, using a target-controlled schedule with a com-
puter-driven syringe (Stelpump, Professor lohan Coetzee 
and Mr Ralph Pinna, Department of Anaesthesiology and 
Central Electronic Services, University of Stellenbosch). 
The target for fentanyl was 5 ng/ml and sufentanil 2 ng/ml. 
Induction of anaesthesia was completed with etomidate 0.2 
mg/kg or thiopentone 2 - 3 mg/kg. -Muscle relaxation was 
obtained with vecuronium 0.1 mg/kg, whereafter endotra-
cheal intubation was performed and the patient was venti-
lated with oxygen (50%) and air to a normal end-tidal car-
bon-dioxide tension. 
The patient's temperature and urine output were moni-
tored. Maintenance fluid consisted of Ringer's lactate and 
hetastarch in volumes adjusted to meet the patient's clinical 
and ,haemodynimuc needs. 
Dobutamine 5 - 20 pg/kg/min or adrenaline 0.05 - 0.1 
pg/kg/rilin and nitroglycerin 0.25 - 1.0 pg/kg/min were 
given as required -to maintain the haemodynamics within 
75% of awake pre-operative values. 
Patients received heparin (2 mg/kg) and the activated 
clotting time (ACT) used to maintain the ACT between 400 
and 500 seconds. At the end of bypass heparin was reversed, 
using protamine sulphate approximately 1.3 times the total 
dose of heparin, or until the ACT was within 10% of the pre-
operative value. 
Once bypass was started, the left ventricle was vented via 
a pulmonary vein and the aortic cross-clamp applied. The car-
dioplegic solution was infused into the aortic root (St Thomas 
II solution gassed with oxygen and kept at 10°C) until asys-
tole was achieved. Thereafter cardioplegia was infused every 
20 minutes. Topical cooling of the heart was also performed. 
The patient was cooled to 28°C for the duration of surgery, 
and the alpha-stat (uncorrected for temperature) method of 
blood gas interpretation was used during hypothermia. 
Once revascularisation was completed, patients were, 
rewarmed to a nasopharyngeal temperature of 35 - 36°C. 
Bypass was then terminated and the patient's circulation sup-
ported as clinically indicated. 
Patients were ventilated postoperatively for 4 - 12 hours 
depending on the cardiovascular and pulmonary status. 
For the purpose of this study, the following were recorded: 
(i) the patient's demographic data, chronic medication, as 
well as cardiovascular status and other cardiovascular risk 
factors; (ii) systolic, diastolic and mean arterial blood pressure 
(SAP, DAP, MAP); (iii) heart rate (HR); (iv) central venous 
pressure (CVP); (v) aortic cross-clamp time (minutes); (vi) 
defibrillation required after unclamping the aorta (joules); 
(vii) lignocaine required after aortic unclamping (mg/kg); 
(viii) phenylephrine required after bypass (mg/kg for the 
duration of the operation); (ix) blood magnesium concentra-
TABLE I. DEMOGRAPHICS, CARDIOVASCULAR STATUS AND PRE-OPERATIVE TREATMENT OF STUDY 
GROUPS (MEAN ± SD) 
Groups 
Total o g MgS04 :2 gMgS04 4gMgS04 6gMgS04 
N 138 31 37 40 30 
Age (yrs) 58.5 ± 11.8 60.2 ± 10.9 56.1 ± 12.3 61.4 ± 10.5 55.9 ± 12.4 
Men/women 105:33 24:7 32:5 23:171 26:4 
BSA (m') 1.9 ± 0.2 1.9 ± 0.2 1.8 ±0.2 1.9 ± 0.5 1.9 ± 0,2 
Hypertension (%) 51 51 33 ,63 53 
Diabetes (%) 18 22 11 25 16 
Angina class* 2.7 ± 0.8 2.7 ±0.9 2.8 ± 1.2 . 3.0 ± 1.2 3.0 ± 0.8 
Exercise class* 2.1 ± 0,6 2.0 ±O,7 2.3 ± 0.9 2.5 ± 0,9 2.4 ± 0.7 
Orthopnoea (%) 23 12 11 301 27' 
13-blocker (%) 90 96 83 82 100 
Calcium antagonist (%) 54 48 67 63 66 
Nitrates (%) 83 51 81 92 83 
Digitalis (%) 7.2 3 16 10 3 
Cardiac failure (%) 3,6 3 0 8 0 
New Q-waves (%) 33 25 37 32 36 
• New York Heart Association class, 
tx'P = 0.033, 
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TABLE II. CARDIOPULMONARY BYPASS AND AORTIC CROSS-CLAMP TIMES AND TREATMENT OF 
VENTRICULAR FmRILLATION (MEAN ± SD) 
Groups 
·0 g MgS04 2 g MgS04 4g MgS04 6g MgS04 
N 
CPB time (min) 












CPB = cardiopulmonary bypass . 
• 6 g diffeno from 2 g and 4 g groups. 
t6 g differ.; from 0 and 2 g groups. 
*4 g differ.; from 0 g group . 
. §2 g differ.; from 0 g group. 
,Before CPB differ.; from afrer CPB (P < 0.001). 
31 37 
95.5 100.1 
± 38.20 ± 31.2 
52.1 56.5 
±17.3 ± 17.0 
41.9 28.9 











±lo4 ± 2.5 
2.6 3.2 
±2.9 ± 3.1 
40 30 
100.1 106.9 
± 33.0 ±36.0 
54.8 60.3 
± 16.0 ±22.9 
37.5 38.1 
± 32.1 ± 26.1 
75 70.0 
115.8 122.7 
± 37.8 ± 53.6 
7.5 13.1 * 
±504 ± 18.5 
0.8 0.8 




± 1.2 ± 1.8 
304 2.5 
±2.6 ± 1.9 
formed with the Student-Newman-Keuls test. Proportions 
were compared with the chi-squared test. If the data were 
not normally distributed, the Mann-Whitney rank sum non-
parametric test was performed. A P-value of < 0.05 was 
accepted as indication of significant differences between 
tion (mmolll); (X) CK-MB fraction (%); (xi) dobutamine 
before and after bypass (Jtg/kg/min); (xii) nitroglycerin 
required before and after bypass (#g/kg/min); (xiii) 
adrenaline required before and after bypass (Jtg/kg/min); 
and (xiv) new Q-waves on a postoperative ECG recorded 24 
hours after bypass. . variables. 
Protocol 
Patients were randomly assigned to receive 0, 2, 4 or 6 g 
magnesium sulphate, which was slowly infused from after 
the induction of anaesthesia and completed at the time the 
aortic cross-clamp was removed. 
If ventricular tachycardia or fibrillation occurred after 
removal of the aortic cross-clamp, the heart was directly 
defibrillated with the following energy sequence: 10, 10, 15, 
15,20 joules (J). If ventricular fibrillation persisted after the 
second 15 J defibrillation, lignocaine was administered into 
the pump (I mg/kg). During reperfusion the coronary perfu-
sion pressure was maintained with the previously specified range. 
Measurements were taken before anaesthesia, before hep-
arinisation, after bypass and completion of the protamine 
sulfate, and 12 hours after bypass. 
CK-MB fraction was only measured before anaesthesia 
and 24 hours after bypass. 
Analysis of data 
Data were analysed with one-way analysis of variance 
(ANOV A) and subsequent multiple comparisons were per-
Results 
Data from 138 patients could be used for analysis. The 
demographics are summarised in Table I. Significant differ-
ences between groups included the proportion of men to 
women, with more women in the 4 g MgS04 group. There 
was also a higher incidence of orthopnoea and paroxysmal 
nocturnal dyspnoea in the 4 g and 6 g MgS04 groups. 
However, the incidence of cardiac failure on pre-operative 
examination was similar between groups. 
Table II shows the cardiopulmonary bypass and aortic 
cross-clamp times that were similar between groups. The 
incidence and amount of joul~s required for defibrillation 
once the aortic cross-clamp was taken off were similar 
between groups. The blood concentration for magnesium 
was higher at the time the aortic cross-clamp was released in 
the magnesium groups when compared with their own ini-
tial value. There were small but significant differences 
between final magnesium values attained as the dose of 
magnesium was increased. 
The haemodynamics for the various groups and steps are 
summarised in Table III. In the control group the heart rate 
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TABLE III. HAEMODYNAMIC VALUES AND DRUGS REQUIRED FOR CIRCULATORY SUPPORT (MEAN ± SD) 
HR SAP DAP CVP Dob Adr TNT 
MgS04 Step (b/min) (mmHg) (mmHg) (mmHg) (}lg/kg/min) (}lg/kg/min) (}lg/kg/min) 
1 64± 15 142 ± 26 75 ± 12 8±3 3.5 ± 1.8 0 0.7 ± 0.3 
Og 2 92 ± 15* 116 ± 17* 65 ± 9*' 10 ± 6.4* 9.3±6.4* 0.2 ± 0.2* 1.3 ± 0.9 
(N= 31) 3 94 ± 13* 121 ± 16* 62±9* ·10 ± 3* 8.0 ± 3.3* 0.2 ± 0.2* 0.9 ± 1.0 
4 90 ± 12* 127 ± 15* 64± 11* 10 ± 3* 8.3 ± 6.3 0.1 ± 0.1 0.9 ±0.9 
1 69± 12 134± 24 76± 19 8±4 3±0 om ± 0 1.5 ± 2.6 
2g 2 92 ± 15* III ± 11* 59± 7* 10 ±4* 8.0 ± 5.0 0.4 ± l.l 1.5 ± 1.7 
(N= 37) 3 99 ± 13* 120 ± 14* 63 ± 8* 11 ±4* 6.9 ±4.2 0.2 ± 0.4 0.6 ±0.7 
4 98 ± 15* 128 ± 15 68 ± 14* 10 ± 3* 6.0 ± 3.0 0.2 ± 0.6 0.7 ±0.7 
1 70± 13 140 ±20 7 ± 11 9±4 4.7 ± 3.0 0.03 ± 0.1 0.5 ± 0.3 
4g 2 97 ± 15* 118 ± 17* 60 ± 9* 11 ±4* 10.5 ± 3.5* 0.4 ± l.l 1.3 ± 1.3* 
(N=40) 3 94± 12* 120 ± 12* 60±11* 11 ±4 9.9 ± 4* 0.13 ± 0.1 1.1 ± 1.'7* 
4 94 ± 15* 126 ± 12* 67 ± 12* 12±5* 7.7 ± 5.8* 0.1 ± 0.1 1.9±5.1* 
1 64± 12 137 ± 21 77 ± 11 9±5 0 0 0.8 ± 0.3 
6g 2 92 ± 14* 120 ± 13* 62± 8* 1O±4 102 ± 5.5* 0.2 ± 0.2* 0.9 ± 0.8* 
(N= 30) 3 94 ± 14* 115 ± 13* 59± 7* 11 ±4 10.7 ± 4.8* 0.2±0.1* 0.5 ± 0.4* 
4 98 ± 15* 128 ± 15 66 ± 11 * 11 ±4 7 ± 4.2* 0.1 ± 0.1 * 0.7 ± 0.7* 
HR;;;; hean rate; SAP, DAP = systolic and diastolic anerial pressure; CVP = central venous pressure; Dob = dobutamine; Adr = adrenaline; TNT = nitroglycerin . 
• Compares the designated value with its own step I. 
tcompares the designated value with similar steps of2 g and 4 g MgSO. groups. 
the blood pressure decreased after induction of anaesthesia 
and remained less than control for the rest of the experi-
ment. The CVP increased once anaesthesia was induced 
and ventilation was started. There was an increase in the 
dobutamine and adrenaline requirements after cardiopul-
monary bypass. A similar pattern was noted for the other 
three groups. 
Significantly more phenylephrine was required for the 
patients who received 6 g MgS04 when compared with the 
other three groups. 
The CK-MB fraction did not increase from the before to 
after values in any of the groups, and the groups did not dif-
fer from one another. The incidence of new Q-waves on the 
ECG after CABG did not differ between groups. 
Discussion 
The protocol used in this model failed to demonstrate any 
beneficial effects of magnesium on reperfusion injury of the 
heart. This is at variance with the theory of the reperfusion 
injury,2~ animal experimentss.9.,0.'4 and some clinical stud-
ies. 15•16 
Published reports suggest that intracellular calcium over-
load is an important factor, and probably the final common 
pathway in causing the reperfusion injury.3.'7 Some authors ' .2 
suggest that free oxygen radical formation precedes the cal-
cium overload, while other data appear to differ. Meissner 
and Morgan'8 demonstrated an early increase in intracellular 
calcium, while Jeremy et al.'9. demonstrated peak calcium 
contractions at approximately 5 minutes after reperfusion is 
started. Thereafter the intracellular calcium concentration 
subsided to a level somewhat in excess of the normal intra-
cellular calcium concentration.6 Drugs that attenuate the rad-
ical formation or intracellular calcium overload lessen the 
extent of the reperfusion injury .5.7 
Magnesium is a physiological calcium antagonist;8 our 
hypothesis was, therefore, that magnesium will reduce the 
reperfusion injury. The hypothesis was further supported by 
data from animal experiments that clearly demonstrated 
beneficial effects when additional magnesium was admini-
stered,9 while a chronic depletion of magnesium resulted in 
an exaggerated reperfusion injury.'o Our own experimental 
data in a porcine model showed that the administration of 
magnesium (30 mg/kg) immediately before the release of a 
I5-minute occlusion of the left anterior descending (LAD) 
artery, resulted in less ventricular arrhythmias and a rapid 
recovery of systolic myocardial function." 
Clinical studies are, however, less clear on the issue of 
magnesium after myocardial infarction. The LIMIT-2 trial '2 
reported an improved outcome if magnesium was adminis-
tered to patients after they suffered a myocardial infarction. 
These results could not be confirmed in the ISIS 4 study Y It 
should, however, be noted that these studies were performed 
in a different setting compared with the present study. The 
LIMIT and ISIS trials gave magnesium to patients some 
time after myocardial infarction, while we gave magnesium 
before reperfusion was started. 
Although the pre-operative (chronic) ischaemic burden 
between our experimental groups could have varied, we 
hypothesised that the real ischaemic insult was the applica-
tion of the aortic cross-clamp. The cross-clamp times 
between our groups were similar and we therefore speculate 
that the degree of myocardial ischaemia, and hence the 
reperfusion injury, was similar in the four study groups. In 
addition, we gave the magnesium before the start of the 
reperfusion in order to have the maximum possible benefit 
early in the reperfusion time. 
There are a number of possible explanations for our fail-
ure to show any advantage to the administration of magne-
sium. 
1. There is no real benefit. Our data were collected in a 
randomised prospective fashion and although the clinician 
collecting the data was not blinded, the principal author was 
unaware of the groups to which the patients were allocated. 
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times) was similar, and the management of the haemody-
namics was similar between the clinicians. Power analyses 
of some of the key results suggest that the number of 
patients included was sufficient for an alpha = 0.05 (varying 
from 70% to> 99%, with the lowest values obtained from 
adrenaline and dobutamine infusions). From this we have to 
conclude that there is no difference in the results and that we 
failed to confirm the hypothesis with our study protocol. 
2. The methods employed to detect the reperfusion injury 
are not sufficiently sensitive to detect stunning. Stunning 
primarily refers to systolic dysfunction, i.e. poor myocardial 
contractility.20 This is best detected with echocardiography. 
We relied on general haemodynamic parameters and the use 
of vaso-active drugs required to restore the circulation to 
predetermined endpoints. However this approach is nonspe-
cific and will not demonstrate small differences. In retro-
spect, this must be regarded as a major limitation in our 
methodology. 
However, reperfusion arrhythmias could be detected reli-
ably and we failed to demonstrate a difference in the inci-
dence or severity of arrhythmias. From this perspective we 
again conclude that the hypothesis was not confirmed, i.e. 
that the magnesium given in this protocol did not affect the 
reperfusion injury. If the arrhythmias were not significantly 
affected by the magnesium it is unlikely that the stunning 
will behave in a different manner. 
3. The blood concentration of the magnesium was not 
sufficient to have an effect. We used doses similar to those 
used in previous studies. The LIMIT-2 trial '2 gave an intra-
venous bolus of 2 g followed by approximately 0.7 mmol 
per hour. Iseri21 reports on the use of 2 g bolus and 0.5 g per 
hour thereafter, while the ISIS-4 study" used a 2 g bolus and 
0.75 g per hour thereafter up to 24 hours. Another clinical 
study22 utilised 6 g over 3 hours followed by 10 g over the 
next 21 hours, while a meta-analysis reports an average 
administration of 0.5 g per hour." Our maximum rate of 
administration was 0.5 g per hour for the 6 g group. 
Our aim was to elevate the blood concentration of mag-
nesium so that at the time the aortic cross-clamp was 
removed we could study the effect of various blood concen-
trations of magnesium on the reperfusion injury. Although 
we achieved a dose-dependent increase in magnesium blood 
concentrations, the differences between groups were rather 
small. 
It is possible that the absence of a more pronounced 
increase in the magnesium concentration can be explained 
by the large volume of distribution for magnesium coupled 
with the rapid renal excretion of the ion. James24 suggests 
that in order to increase the level of magnesium significantly 
a large initial bolus be given (40 - 60 mg/kg), followed by a 
continuous infusion of 15 - 30 mg/kg/h. 
However, further increase in blood concentrations may 
not be warranted in the peri-operative period as there is a 
potential risk of poor myocardial function and/or conduction 
disturbance after hypothermia, cardioplegia and cardiac 
surgery. Accordingly we did not think it would be ethically 
justifiable to use higher doses of magnesium for a clinical 
study in these particular settings. 
What was unexpected, however, was the fact that the 
group that did not receive magnesium demonstrated an 
increase in magnesium blood concentration once the aortic 
cross-clamp was removed. Previous studies have shown that 
magnesium concentration decreases after cardiopulmonary 
bypass (CPB), probably owing to acute haemodilution 
caused by the clear prime of the CPB circuit.2526 The most 
probable explanation for the increase in the group not 
receiving magnesium is the use of the St Thomas solution, 
which contains a significant concentration of magnesium. 
This explanation is supported by a study conducted by 
Manners and Nielsen27 who also showed an increase in mag-
nesium concentration after bypass when St Thomas solution 
was used. The increase they reported was, however, smaller 
than that which we have shown and the difference may well 
be ascribed to a difference in the volumes of cardioplegia 
used. They only infused cardioplegia 45 minutes after initial 
arrest, while we used cardioplegia every 15 - 20 minutes. 
4. An alternative, although improbable, explanation for 
our failure to confirm our hypothesis may be that the 
myocardial protection in our groups was such that there was 
little myocardial ischaemia and hence only an insignificant 
degree of reperfusion injury. The liberal use of beta-adrener-
gic blockers, halothane, arresting the heart in diastole, 
proper venting of the left ventricle, hypothermia and the use 
of oxygenated cardioplegia all contribute towards effective 
myocardial protection.28 However, the fact that a significant 
number of patients had reperfusion arrhythmias and that the 
inotropic requirements post-CPB were higher than those 
used before CPB, argue against the absence of a reperfusion 
injury . 
5. St Thomas cardioplegic solution contains a significant 
amount of magnesium. With the liberal use of cardioplegia 
the myocardial intra- and extracellular magnesium could 
have attained a supranormal value and exerted a maximum 
protective effect - hence the failure to demonstrate any 
beneficial effects from additional magnesium as admini-
stered in our protocol. 
6. The model we used for this study, i.e. aortic cross-
clamp, may not be appropriate. A number of drugs were 
used, there was variation in the duration of cross-clamp, and 
the quality of the surgical reperfusion varied. In addition, 
there was a significant number of new Q-waves recorded, 
i.e. indicating cell death. However, because aortic cross-
clamping invariably causes some degree of ischaemia, and 
because the incidence of Q-waves as well as other variable 
factors was equally distributed between groups, we think 
that the model and the comparison are indeed valid. 
In conclusion, we failed to demonstrate beneficial effects 
of additional magnesium before the release of the aortic 
cross-clamp during cardiac surgery. A higher blood concen-
tration of magnesium than that which we attained may well 
be required to demonstrate beneficial effects. However, 
because of the possible negative effects on cardiac perfor-
mance in the circumstances of cardiac surgery, this may 
well be the limitation of magnesium as a therapeutic option 
in this particular scenario. 
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